---
figid: PMC6615683__zbc0291908040006
figlink: pmc/articles/PMC6615683/figure/F6/
number: Figure 6
caption: Model describing the putative mechanism of synergetic interaction between
  PFK158 and erlotinib in WT and mutEGFR NSCLC cell lines. In mutEGFR cells, chronic
  inhibition of EGFR signaling by erlotinib promotes reactivation of the MAPK pathway
  thereby stimulating PFKFB3 transcription via CREB1 binding to the PFKFB3 promoter.
  Enhanced PFKFB3 transcription compensates for the loss of protein because of targeted
  degradation by the proteasome and promotes cell survival. In WT-EGFR cells, prolonged
  erlotinib exposure stimulates EGFR signaling which, in turn, up-regulates PFKFB3
  expression by an unknown mechanism and promotes cell survival. PFKFB3 inhibition
  with PFK158 blocks the prosurvival function of PFKFB3 resulting in a marked increase
  in cytotoxicity when used in combination with erlotinib. Solid arrows indicate established
  direct regulations of downstream targets. Dashed arrows indicate indirect activation
  where intermediate steps are involved but are not specified in this schematic.
pmcid: PMC6615683
papertitle: Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity
  in response to EGFR signaling contributes to nonâ€“small cell lung cancer cell survival.
reftext: Nadiia Lypova, et al. J Biol Chem. 2019 Jul 5;294(27):10530-10543.
pmc_ranked_result_index: '12529'
pathway_score: 0.9638529
filename: zbc0291908040006.jpg
figtitle: Model describing the putative mechanism of synergetic interaction between
  PFK158 and erlotinib in WT and mutEGFR NSCLC cell lines
year: '2019'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6615683__zbc0291908040006.html
  '@type': Dataset
  description: Model describing the putative mechanism of synergetic interaction between
    PFK158 and erlotinib in WT and mutEGFR NSCLC cell lines. In mutEGFR cells, chronic
    inhibition of EGFR signaling by erlotinib promotes reactivation of the MAPK pathway
    thereby stimulating PFKFB3 transcription via CREB1 binding to the PFKFB3 promoter.
    Enhanced PFKFB3 transcription compensates for the loss of protein because of targeted
    degradation by the proteasome and promotes cell survival. In WT-EGFR cells, prolonged
    erlotinib exposure stimulates EGFR signaling which, in turn, up-regulates PFKFB3
    expression by an unknown mechanism and promotes cell survival. PFKFB3 inhibition
    with PFK158 blocks the prosurvival function of PFKFB3 resulting in a marked increase
    in cytotoxicity when used in combination with erlotinib. Solid arrows indicate
    established direct regulations of downstream targets. Dashed arrows indicate indirect
    activation where intermediate steps are involved but are not specified in this
    schematic.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - HRAS
  - KRAS
  - NRAS
  - PFKFB3
  - MAPK3
  - MAPK1
  - RPS6KA1
  - RPS6KA3
  - RPS6KB1
  - RPS6KB2
  - RPS6KA5
  - RPS6KA6
  - RPS6KA2
  - RPS6KA4
  - CREB1
genes:
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PFKFB3
  symbol: PFKFB3
  source: hgnc_symbol
  hgnc_symbol: PFKFB3
  entrez: '5209'
- word: PFKFB3
  symbol: PFKFB3
  source: hgnc_symbol
  hgnc_symbol: PFKFB3
  entrez: '5209'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA1
  entrez: '6195'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA3
  entrez: '6197'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KB2
  entrez: '6199'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA5
  entrez: '9252'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA6
  entrez: '27330'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA2
  entrez: '6196'
- word: RSK
  symbol: RSK
  source: bioentities_symbol
  hgnc_symbol: RPS6KA4
  entrez: '8986'
- word: PFKFB3
  symbol: PFKFB3
  source: hgnc_symbol
  hgnc_symbol: PFKFB3
  entrez: '5209'
- word: CREB1
  symbol: CREB1
  source: hgnc_symbol
  hgnc_symbol: CREB1
  entrez: '1385'
chemicals: []
diseases: []
---
